Takeda Oncology Executive and Leadership Team

Marcelo Barretta, the Chief Financial Officer at Takeda Oncology, directs all fiscal planning and capital allocation strategies. Overseeing the financial health of the oncology specialty business unit, the Chief Financial Officer ensures that resource distribution aligns with long-term research and development goals. This leadership role involves managing complex budgetary frameworks to support the production of oncology therapies across international markets. By optimizing cost structures and investment portfolios, Marcelo Barretta directly impacts the ability of the organization to scale manufacturing operations. The Chief Financial Officer maintains rigorous oversight of fiscal compliance, providing the necessary stability for the company to pursue aggressive growth in the pharmaceutical sector. Through precise financial modeling and risk assessment, Barretta secures the capital required for ongoing clinical advancements, ultimately strengthening the market position of the business unit within the competitive global landscape.

Christophe Bianchi, the President at Takeda Oncology, directs the strategic vision and commercial execution for the oncology specialty business unit. Overseeing the development of innovative therapies, the President ensures that the organization maintains a strong focus on patient outcomes and scientific excellence. This leadership role involves navigating complex regulatory environments and driving market expansion across North American and international territories. By fostering partnerships with research institutions and healthcare providers, Christophe Bianchi directly impacts the commercial success of the oncology portfolio. The President manages the integration of new therapeutic candidates into the production pipeline, ensuring that the company remains at the forefront of pharmaceutical manufacturing. Through decisive leadership and a commitment to clinical advancement, Bianchi drives the long-term growth of the business unit, solidifying the reputation of the organization as a leader in the global oncology market.

Rob Smith, the President at Takeda Oncology, architects the operational infrastructure and supply chain logistics for the oncology specialty business unit. Overseeing the manufacturing and distribution of oncology therapies, the President ensures that production capabilities meet the growing demand for specialized medical treatments. This leadership role involves optimizing manufacturing processes to maintain high quality standards while scaling operations to reach diverse patient populations. By implementing advanced supply chain technologies, Rob Smith directly impacts the reliability and accessibility of the product portfolio. The President collaborates with global logistics partners to ensure seamless delivery of therapies across international borders. Through rigorous operational oversight and a focus on manufacturing efficiency, Smith supports the overall mission of the organization, ensuring that critical oncology treatments reach patients in need with consistency and precision, thereby enhancing the operational footprint of the company.

Teresa Bitetti, the Global President, Oncology Business Unit at Takeda Oncology, directs the overarching strategy and global market presence for the entire oncology portfolio. Overseeing the alignment of research, development, and commercialization efforts, the Global President, Oncology Business Unit ensures that the organization delivers transformative therapies to patients worldwide. This leadership role involves setting the long-term vision for the business unit and managing relationships with key stakeholders in the global pharmaceutical industry. By championing innovation and fostering a culture of scientific rigor, Teresa Bitetti directly impacts the competitive standing of the company. The Global President, Oncology Business Unit monitors market trends and therapeutic advancements to guide the strategic direction of the organization. Through visionary leadership and a focus on global health impact, Bitetti drives the expansion of the oncology business, ensuring that the company remains a premier provider of specialized cancer treatments.

Tawnee Friedrich, the Chief Of Staff, GMAO at Takeda Oncology, coordinates cross-functional initiatives and streamlines executive decision-making processes. Overseeing the operational flow between the Global Medical Affairs Oncology division and other internal departments, the Chief Of Staff, GMAO ensures that strategic objectives receive consistent focus. This leadership role involves managing high-level communications and facilitating alignment across diverse teams to accelerate the delivery of oncology therapies. By refining internal workflows and project management standards, Tawnee Friedrich directly impacts the efficiency of the organization. The Chief Of Staff, GMAO monitors progress on key milestones, ensuring that the business unit meets its operational targets in the competitive pharmaceutical market. Through proactive management of organizational priorities and stakeholder engagement, Friedrich fosters a collaborative environment that supports the broader mission of delivering innovative medical solutions to patients across the globe.